Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODeFIRe-1: MRT-2359 + Apalutamide in Castration-Resistant Prostate Cancer
NCT07745361Phase 2Recruiting
- Sponsor
- Monte Rosa Therapeutics
- Start
- Aug 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of MRT-2359 in castration-resistant prostate cancer (CRPC), sponsored by Monte Rosa Therapeutics. Started Aug 2026; status: recruiting.
02
Drugs
MRT-2359
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07745361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07745361.